Adjuvant therapy

Midgley, Rachel S J; Kerr, D J
November 2000
BMJ: British Medical Journal (International Edition);11/11/2000, Vol. 321 Issue 7270, p1208
Academic Journal
Discusses the development of adjuvant therapy in the treatment of colorectal cancer. Statistics for the number of patients who develop recurrence after resection; Pharmacology and benefits of fluorouracil-based adjuvant chemotherapy; Controversy surrounding such therapeutic strategies; Outlook for the use of additional drugs, immunotherapy, and gene therapy in adjuvant treatment.


Related Articles

  • Progress in Colorectal Cancer Chemotherapy: How Far Have We Come, How Far to Go? Royce, M.E.; Hoff, P.M.; Pazdur, R. // Drugs & Aging;2000, Vol. 17 Issue 3, p201 

    Fluorouracil has been the mainstay of treatment for colorectal cancer (CRC) for almost 40 years. Various schedules and biochemical modulators have been investigated in an attempt to improve the therapeutic efficacy of fluorouracil. To date, fluorouracil plus folinic acid represents the standard...

  • Chemotherapy of chemically-induced colorectal tumours. Gilbert, J. M.; Thompson, E. M.; Slavin, G.; Kark, A. E. // Journal of the Royal Society of Medicine;Jun1983, Vol. 76 Issue 6, p467 

    Benign and malignant tumours were induced in the large bowel of rats by the carcinogen 1,2-dimethylhydrazine (DMH). Benign tumours appeared from week 20 onwards and malignant tumours from week 30. 5-Fluorouracil was administered intraperitoneally in maximally tolerated doses from week 26 onwards...

  • Fluorouracil.  // Reactions Weekly;5/8/2010, Issue 1300, p22 

    The article describes the case of a 79-year-old female patient who acquired hyperammonaemia and impaired consciousness while taking fluorouracil for metastatic unresectable colon cancer.

  • Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies.  // JNCI: Journal of the National Cancer Institute;04/02/97, Vol. 89 Issue 7, p497 

    Assesses the effects on recurrence and survival of administering fluorouracil-based chemotherapy by portal vein infusion (PVI) after colorectal cancer surgery. Meta-analysis of 4000 patients in ten studies; Comparison of PVI and no further treatment; Effect of PVI in different subgroups of...

  • Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. Berlin, Jordan; Posey, James; Tchekmedyian, Simon; Hu, Eddie; Chan, David; Malik, Imtiaz; Yang, Liqiang; Amado, Rafael G.; Hecht, J. Randolph // Clinical Cancer Update;Dec2007, Vol. 1 Issue 1, p50 

    Purpose: Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor and is indicated for patients with metastatic colorectal cancer (mCRC) who have experienced disease progression after standard chemotherapy. We conducted this phase II study to assess...

  • Severe liver dysfunction and safe use of 5.fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma. Tural, Deniz; Akar, Emre; Öztürk, Mehmet Akif; Yıldız, Özcan; Turna, Hande; Serdengeçti, Süheyla // Journal of Cancer Research & Therapeutics;Jul-Sep2014, Vol. 10 Issue 3, p745 

    The liver is the most frequent site of metastases in colorectal cancer. Commonly used anticancer drugs in colorectal cancer are 5-fluorouracil, oxaliplatin and irinotecan 5-fluorouracil (5-FU) and oxaliplatin have very few numbers of studies that support their safety in hepatic dysfunction, but...

  • Effect of combination therapy of siRNA targeting growth hormone receptor and 5-fluorouracil in hepatic metastasis of colon cancer. DONG ZHOU; YI ZHANG; DAOMING LIANG; YONG YUAN; DEMIAO ZENG; JIAYONG CHEN; JIE YANG // Oncology Letters;Dec2015, Vol. 10 Issue 6, p3505 

    The aim of this study was to investigate the effects of small interfering RNA (siRNA) targeting human growth hormone receptor (hGHR) combined with 5-fluorouracil (5-FU) on the hepatic metastasis of colon cancer. The animal model of liver metastases using human SW480 colon cancer cells was...

  • A phase 3 non-inferiority study of 5-FU/ l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. Yasui, Hirofumi; Muro, Kei; Shimada, Yasuhiro; Tsuji, Akihito; Sameshima, Shinichi; Baba, Hideo; Satoh, Taroh; Denda, Tadamichi; Ina, Kenji; Nishina, Tomohiro; Yamaguchi, Kensei; Esaki, Taito; Tokunaga, Shinya; Kuwano, Hiroyuki; Boku, Narikazu; Komatsu, Yoshito; Watanabe, Masahiko; Hyodo, Ichinosuke; Morita, Satoshi; Sugihara, Kenichi // Journal of Cancer Research & Clinical Oncology;Jan2015, Vol. 141 Issue 1, p153 

    Purpose: The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall...

  • HGUE-C-1 is an atypical and novel colon carcinoma cell line. Grasso, Silvina; Martínez-Lacaci, Isabel; Barberá, Víctor Manuel; Castillejo, Adela; Soto, José Luis; Gallego-Plazas, Javier; López-Riquelme, Natividad; García-Morales, Pilar; Mata-Balaguer, Trinidad; Ferragut, José Antonio; Saceda, Miguel // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Colorectal carcinoma is a common cause of cancer. Adjuvant treatments include: 5-fluorouracil administered together with folinic acid, or more recently, oral fluoropyrimidines such as capecitabine, in combination with oxaliplatin or irinotecan. Metastatic colorectal cancer patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics